US FDA highlights birth defect risks of valproate products
This article was originally published in Scrip
Executive Summary
The US FDA has notified healthcare professionals and patients that valproate sodium and related products – valproic acid and divalproex sodium – increase the risk of birth defects in babies exposed during pregnancy.